Medicare

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    Medicare Paid More Than the Bill, Because Apparently Even the Bill Needs Oversight

    ByHugh Jass

    I have spent the morning exhuming a HHS-OIG audit, and the document coughed. The review examined 801 selected Medicare Part B claim lines from payments made in 2022 and 2023. Among them were 138 incorrect lines that produced at least $140,182 in overpayments. Another 31 lines, totaling $76,640, lacked supporting documentation. This is not proof that every claim was improper; it is a selected sample with enough administrative thunder to make the filing cabinet nervous.

    The target here is not patients or an accusation that providers acted intentionally. The target is the payment-control machinery: the edits, reviews, and safeguards assigned to notice when Medicare money is headed somewhere it should not go. Wisconsin Physicians Service Insurance Corporation already had system edits and follow-up procedures intended to identify overpayments. HHS-OIG still found incorrect payments and unsupported claim lines in the reviewed sample, which suggests the controls were present in the same way a smoke detector is present during a very organized kitchen fire.

    Hugh Jass Serious Investigative Reporting has located the central contradiction: the claim was important enough to generate edits, reviews, and recommendations, but not important enough to stop the money first. The system had a process for checking the paperwork, a process for checking the checking, and apparently a later process for discovering that the first two processes had allowed the money to leave the building wearing sunglasses.

    HHS-OIG recommended corrective action, and WPS concurred with those recommendations. The audit does not establish a recovery outcome, so the responsible sentence ends there. That restraint is called evidence, a rare substance often found in the same room as a spreadsheet but never invited to the budget meeting.

    The invoice, in other words, survived quality control by becoming a payment. Before the money moved, the bill was suspicious. After the money moved, it appears to have received diplomatic immunity. Medicare oversight is supposed to catch mistakes; in this case, the auditors had to audit the audit trail, proving once again that paperwork is not useless. It is merely waiting for another layer of paperwork to explain why it failed.

  • |

    If Prices Can Fall Now, Who Approved the Old Ones?

    ByHarlan Quill

    I have spent enough time with budgets to know that when a Medicare drug price falls after negotiation, the old price deserves an audit—not a standing ovation. The usual sales pitch says Medicare must accept whatever number arrives in the envelope, as though drug pricing were a weather event and not a market with lawyers. Then bargaining happens, the bill gets smaller, and “impossible” suddenly develops a discount code.

    The exact before-and-after figures may be illustrative, and lower prices do not automatically shrink every patient’s copay. But the practical point survives the fine print: negotiation can reduce public spending and may ease the bill at the pharmacy counter. The people defending the old system now have to explain why savings were forbidden until someone asked for them. The national drug-pricing spreadsheet has ruled that “unavoidable” was apparently the premium tier, complete with a lobbyist and no cancellation button.

  • |

    Tiny Tweak, New Monopoly: Evergreening Shouldn’t Mean a Bigger Bill

    ByJustin Jest

    I’m not saying the billion-dollar backroom worships a stopwatch, but the patent expires and—boom—“innovation” shows up as an extended-release, a new coating, or a combo pill. Same original drug, new paperwork, new dose, with that fresh little seal slapped on like it’s a brand-new invention. Not every reformulation is a real breakthrough; sometimes it’s just the legal version of swapping a street sign and calling it “progress.”

    When competition waits, Medicare keeps paying while the price clock does a victory lap under a new nameplate. A small change shouldn’t mean a bigger bill—yet the system treats “tiny tweak” like it’s the next chapter in monopoly fanfic, just with higher invoices.

  • |

    Wall Street’s New Favorite Dance: The Medicare Money Shuffle

    ByJustin Jest

    Picture the dance floor at a swanky Wall Street gala, where every beat syncs perfectly with Medicare’s cascading cash flow. It’s not a fundraiser—it’s a celebration, where taxpayer dollars pirouette elegantly into the pockets of America’s financial titans, who are somehow always in step with ‘limited competition’ and ‘ever-growing margins.’

    Think of it as a public funds tango; a dance we never learned, yet we’re forever financing. High prices are the new sheet music—every note drenched in champagne and caviar, while the taxpayers sit in the bleachers, wondering if they missed the invite or just funded it. Welcome to the ultimate societal shoulder shrug, where public funding becomes Wall Street’s limitless conga line!

  • |

    The Patent Labyrinth: Why Cheaper Meds Are Stuck in Traffic

    ByLee Keybum

    Big Pharma’s favorite maze game? Patents. They claim innovation, yet leave generic drugs entangled in legal red tape longer than a DMV line on a Monday morning. It’s the classic bait-and-switch: promise a cure, deliver a price tag thicker than a lawyer’s billable hour.

    While pharmaceutical giants wax poetic about breakthrough treatments, what they really offer is a roadmap to higher costs. Consider it a toll booth nightmare where your wallet holds its breath as if it’s being drafted by your gym contractor. With every delay, there’s another bureaucratic hurdle—and we’re all just paying the fare for the privilege.

  • |

    Medicare’s Two-Step: Tax Dollars in, Bills Out

    ByHarlan Quill

    Picture this: you invest in a promising apple orchard, only to be charged full price at the market for the very apples your money helped grow. That’s the nimble shuffle our taxpayer dollars perform every time they back scientific breakthroughs, only to watch drug prices soar beyond reach. It’s a curious choreography where generosity ends up footing the bill twice. Pay to innovate, pay to medicate—rinse, repeat.

    Here lies the elegant inconsistency: public funds fuel discovery, yet it’s private accounts that reap the rewards. Much like watching the orchestra outplay the maestro, pharmaceutical companies take a public encore with private results. Medicare, meanwhile, graciously steps in with taxpayer funds yet again, covering costs in a spectacle that could make even the slickest illusionist envious. Behold, the merry-go-round where public funds twist into private gains—a show where the audience pays for both the curtain and the act.

  • |

    The Medicare Marathon: Sidestepping the Corporate Hurdles

    ByHarlan Quill

    Medicare these days resembles a marathon where seniors are the athletes, yet the finish line keeps moving at the whim of corporate sponsors. The noble promise of Medicare comes with a side order of boardroom influence—almost as if healthcare policies were auctioned off to the highest bidder behind closed doors.

    If navigating Medicare were like running a race, the water stations would be staffed by pharmaceutical execs charging for each drop. Meanwhile, seniors jog along, dodging hurdles in the form of overpriced prescriptions and benefit cutbacks. The real prize seems reserved for those in the luxury boxes, watching the spectacle unfold without breaking a sweat.

  • |

    When a Virtual Check‑In Feels Like a Paperwork Excuse: OIG Unearths $2.26 Million in Sketchy Remote Visits

    ByHugh Jass

    In an April 23, 2026 audit from the Office of Inspector General (OIG), a long-hidden bureaucratic gem emerged—approximately $2.26 million in potentially improper Medicare payments for virtual check-ins and e-visits. Reading like the diary nobody locked, this audit finds that something was amiss in the virtual halls of healthcare billing.

    This isn’t just about imaginary band-aids on imagined cuts. It’s about weaknesses in oversight that allowed these virtual care payments to balloon into multimillion-dollar windfalls, all while CMS was haunted by gaps in system edits and provider education. The very nature of paperwork itself stands accused of duplicity.

    The OIG report breaks it down: around $1.96 million tied to virtual check-ins coincided suspiciously with recent or next-day Evaluation/Management visits. Meanwhile, duplicate billing during e-visits added another $298,200 to the tab. In total, 173,287 services went unnoticed under timelines tighter than a bureaucrat’s grip on their favorite pen.

    No, it’s not fraud; we’re talking ‘potentially improper’—a distinction as sharp and necessary as the label on a mystery envelope that says, ‘Do Not Open.’ The blame lies partly with missing system edits in CMS and the MACs, compounded by bewildered providers deciphering modifiers like an undecided jury.

    The Office of Inspector General, with the calm gravitas of a librarian discovering a hidden annex, offered a roadmap: implement system edits (which CMS accepted), fortify code descriptions (less enthusiasm there), and bolster provider education (agreed upon with the eagerness of a clerk discovering extra forms to file).

    So why should this matter? Because it’s taxpayer money squirming away through administrative fissures. The report’s findings underscore just how bizarrely captivating paperwork can be—we don’t always see the full story unless someone turns on the filing cabinet’s lamp.

    Remember: this isn’t just a tale of fiscal oversight missing a beat. It’s about the modifiers that walked in wearing suspiciously innocent labels, revealing a system that promises future improvements. Yet, even as edits loom, expect the receipts to keep sweating.

    Sources

End of content

End of content